Merck: Q4 in line with expectations
(CercleFinance.com) - Merck has reported Q4 2018 adjusted EPS that is up 6% at 1.
04 dollar, in line with the consensus, with revenue up 5% at 11 billion dollars (+8% at constant exchange rates).
For full-year 2018, the pharmaceutical giant achieved adjusted EPS of 4.34 dollars, with revenues of 42.3 billion dollars, in line with its target ranges posted three months ago.
For fiscal year 2019, the New Jersey-based group (known as MSD outside North America) expects adjusted EPS of 4.57 dollars to 4.72 dollars and revenues of 43.2 billion to 44.7 billion dollars.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
04 dollar, in line with the consensus, with revenue up 5% at 11 billion dollars (+8% at constant exchange rates).
For full-year 2018, the pharmaceutical giant achieved adjusted EPS of 4.34 dollars, with revenues of 42.3 billion dollars, in line with its target ranges posted three months ago.
For fiscal year 2019, the New Jersey-based group (known as MSD outside North America) expects adjusted EPS of 4.57 dollars to 4.72 dollars and revenues of 43.2 billion to 44.7 billion dollars.
Copyright (c) 2019 CercleFinance.com. All rights reserved.